Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer

Jianhua Chang, Yi‐Long Wu, Shun Lü, Jie Wang, Tony Mok, Li Zhang, Jifeng Feng, Lin Wu, Hai‐Yan Tu, Yiping Zhang, Alexander Luft, Jianying Zhou, Zhiyong Ma, You Lü, Chengping Hu, Yuankai Shi, Elena Poddubskaya, Ross A. Soo, Yee Hong Chia, John R. Penrod, Fiona Taylor, Rachael Lawrance, Steven I. Blum, Xiaowu Sun, A. Juarez-Garcia, Alejandro Moreno‐Koehler, Ang Li, Amy Li, Ying Cheng